Elan

Elan OCF Margin

The Operating Cash Flow Margin of Elan (6099.T) as of Oct 9, 2026 is 7.73 %. In the previous year, Operating Cash Flow Margin was 9.47 % — a change of -18.39% (lower).

OCF Margin

7.73 %

YoY

-18.39%

Last updated:

Operating Cash Flow Margin of Elan is 2025 7.73 % . Operating Cash Flow Margin of Elan was 2024 9.47 % . It decreases by -18.39% lower compared to the previous year.

The Elan OCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF Margin
Date
OCF Margin
Jan 1, 2018
6.41 JPY
Jan 1, 2019
3.62 JPY
Jan 1, 2020
7.48 JPY
Jan 1, 2021
6.66 JPY
Jan 1, 2022
4.36 JPY
Jan 1, 2023
4.30 JPY
Jan 1, 2024
9.47 JPY
Jan 1, 2025
7.73 JPY
The Elan OCF Margin history
YEAROCF MarginYoY
7.73 %-18.39%
9.47 %+120.32%
4.30 %-1.42%
4.36 %-34.50%
6.66 %-10.94%
7.48 %+106.44%
3.62 %-43.50%
6.41 %+211.78%
2.06 %-40.84%
3.47 %-3.12%
3.59 %+1.15%
3.55 %—
Access this data via the Eulerpool API

Elan Stock analysis

What does Elan do? Elan Corp is an Irish pharmaceutical company specializing in the research, development, and marketing of medications for neurological and autoimmune diseases. The company was founded in 1969 under the name Athlone Laboratories and has since undergone significant changes in both its business fields and its name. In 1996, the company was renamed Elan Corporation, a name it still holds today. At that time, the company primarily focused on researching and developing medications for Alzheimer's and Parkinson's diseases. However, in the following years, the company shifted its focus more towards treating autoimmune diseases such as multiple sclerosis and Crohn's disease. Elan Corp's business model is based on the development of medications through research and development as well as the acquisition of established therapeutics. One key component of the product portfolio is the medication Tysabri, which was developed in collaboration with Biogen Idec. It is used to treat multiple sclerosis patients and is one of Elan's top-selling medications, contributing significantly to the company's success. Elan Corp consists of three main business areas: 1. Biopharmaceuticals This division is responsible for the research and development of medications for neurological diseases such as Alzheimer's, Parkinson's, and multiple sclerosis. Some of the key products in this area, in addition to Tysabri, include Axona, a nutritional supplement to enhance cognitive function in Alzheimer's patients, and Zanaflex, which is used to treat muscle spasms in the majority of multiple sclerosis patients. 2. Neurology In this division, Elan focuses on the marketing and distribution of nerve and pain medications, as well as products for treating infections. Some of the key products in this area are Skelaxin, a muscle relaxant for pain and muscle spasms, and Biaxin, an antibiotic for treating infections. 3. Medical Technology Elan Corp's medical technology division specializes in the development and marketing of infusion pumps. The company primarily offers its products and services in the United States and Europe and holds a strong position in this market. Elan Corp is a company with a strong focus on research and development. Its key products are medications for treating neurological and autoimmune diseases, with Tysabri being the most well-known and successful. The company has undergone significant changes over the years and now focuses on developing medications for autoimmune diseases in the neurology field. With a strong emphasis on research and development, as well as the acquisition of established therapeutics, Elan Corp is an important player in the pharmaceutical industry and is expected to continue growing and succeeding in the future. Elan is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Elan stock

Operating Cash Flow Margin of Elan is 7.73 % in 2025.

Operating Cash Flow Margin of Elan changed from 9.47 % to 7.73 %, representing a -18.39% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow Margin Elan since 2006 – with annual values, charts, and detailed analysis.

OCF margin measures the percentage of revenue converted into operating cash flow. It indicates cash generation efficiency from core business operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow Margin's Elan with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Cash Flow Margin.

Access this data via the Eulerpool API

Margins — Elan

All Key Metrics — Elan